Preclinical pharmacology of docetaxel

European Journal of Cancer

Volumn 31, Issue 1004, 1995, Pages

  Bissery, M C ^a  

^a NONE

Author keywords

antitumour efficacy; docetaxel; mechanism of action; pharmacokinetics; resistance; toxicology

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; MICE; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0028882838     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00357-O     Document Type: Article

References (42)

1. Plant antitumour agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifolia
2. New natural products under development at the National Cancer Institute
3. Taxol: an antimitotic agent with a new mechanism of action
4. Taxol a novel investigational antimicrotubule agent
5. Le Taxotere: des aiguilles d'if a la clinique
6. The cytoskeleton and cellular movements: microtubules
7. Studies with RP 56976 (Taxotere): a semi-synthetic analog of taxol
8. Relationships between the structure of taxol analogues and their antimitotic activity
9. Assembly of purified GDP-tubulin into microtubules induced by RP 56976 and paclitaxel: reversibility, ligand stoiehiometry and competition
10. Thermodynamics of ligandinduced assembly of tubulin
11. Differential effects of Taxol and Taxotere (RP56976, NSC628503) on Tau and MAP2 containing microtubules
12. Solution structure of microtubules induced by the side chain taxol analogue Taxotere to 3 nm resolution
13. ®) in P388 cell line
14. Effects of Taxotere on murine and human tumor cell lines
15. Differential cytotoxie effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro
16. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines
17. Taxotere: antitumor activity and pharmacokinetics in mice
18. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells
19. Experimental antitumour activity of Taxotere (RP 56976, NSC 628503), a taxol analogue
20. ®) efficacy as a single agent or in combination against mammary tumors in mice
21. ®)
22. Antitumor activity of Taxotere (RP 56976, NSC 628503), a new Taxol analog, in experimental ovarian cancer
23. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts
24. Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical, and cross-resistant studies
25. Taxol: mechanisms of action and resistance
26. ®) resistant human breast carcinoma (Calcl8/TXT) and murine leukemic (P388/TXT) cell lines
27. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly
28. Docetaxel sensitive and insensitive mammary adenocarcinomas contain different polypeptides related to brain MAP-2 protein
29. Reversal of resistance of taxol and Taxotere in a human myeloma cell line model of MDR1
30. Reversal of resistance to Taxol and Taxotere by dexniguldipine-HCI: dose-dependent modulation in various human MDR cell lines
31. Combined effects of edatrexate with Taxol and Taxotere against breast cancer cell growth
32. Radiation sensitizing effects of Taxotere
33. In vivo evaluation of Taxotere (RP 56976, NSC 628503) in combination with cisplatin, doxorubicin or vincristine
34. Taxotere synergistic combination with cyclophosphamide, etoposide and 5-fluorouracil in mouse tumor models
35. Preclinical pharmacology and toxicology of Taxotere (RP 56976, NSC 628503)
36. Kinetics, distribution, metabolism, and excretion of radiolabelled Taxotere in mice and dogs
37. Pharmacokinetics and metabolism of Taxotere™ (Docetaxel)
38. Isolation, identification, synthesis and biological activities of docetaxel metabolites
39. Metabolism of taxoid drugs
40. Docetaxel (RP56976, NSC628503): current status of development
41. Paclitaxel (Taxol™) and docetaxel (Taxotere™): not simple two of a kind